CURRICULUM VITAE: RUTH ISOBEL OHLSEN Present post: Research Worker, IMPACT Team (01.10.2009 ) Division of Psychological Medicine and Psychiatry, with attachment to MRC SGDP Centre), The Institute of Psychiatry at King’s College London (IOP KCL) Email: Ruth.Ohlsen@kcl.ac.uk Qualifications Doctor of Philosophy (King’s College, University of London) Title: Antipsychotics and schizophrenia: a model for obesity? Registered General Nurse (RGN) Registered Mental Nurse (RMN) Diploma of Nutrition (Dip Nut) Employment History September 2009-present: Clinical research worker, IMPACT, PUMP and GAP Teams • IMPACT Team: Researcher: assisting with the design and implementation of a randomised controlled trial of a Health Promotion Intervention in people with severe mental illness , including liaising with clinical personnel across South London and Maudsley, Oxleas and East Sussex NHS Trust. Recruitment of participants, data collection and data entry • PUMP/GAP Teams: Researcher: assisting with clinical data collection and recruitment (including administering clinical rating scales and phlebotomy) • IMPACT/PUMP/Gap Teams: provision of training in clinical rating scales to researchers (PANSS, LUNSERS, ANNSERS) May 2007- September 2009: Clinical Research Nurse “H” Grade, MRC SGDP Centre and Division of Psychological Medicine, Institute of Psychiatry, London. From March 2008 attached to Genetics and Psychosis (GAP) Study Team Activity • Production of a paper on aripiprazole and antipsychotic-weight gain, writing of review papers on cost-effectiveness of antipsychotics, latest advances in the treatment of bipolar affective disorder, and use of aripiprazole in the treatment of schizophrenia • Re-consenting patients for transcriptomics sampling GAP study, design of databases for this and entry of data; assisting with training of researchers within the GAP team in clinical rating scales. • Collation of subject data for diagnosis, development of a cross-referencing diagnostic tool (Using SCAN and IGCL) for retrospective diagnosis and data entry from the GAP study. • PhD Student: (“Antipsychotics and Schizophrenia: A model for obesity?”, Supervision by Dr Shubulade Smith, Dr Katherine Aitchison and Professor Janet Treasure) (submitted August 2009) August 2006- January 2007: Nurse Adviser, Innovex UK attached to Janssen-Cilag “Road to Recovery” Mental Health Programme. • This position involved liaising with and lecturing to NHS professionals in North London, Cambridgeshire, Bedfordshire, Essex and Hertfordshire on Clinical Practice, medication
management, Psychopharmacology, Administration of Clinical Rating Scales and Concordance training. October 2004 – August 2006: Clinical Research Nurse, “H” Grade, Division of Psychological Medicine, Institute of Psychiatry, DeCrespigny Park, London SE5 8AF Activity: • Researcher: RIS –SCH-4045: Early vs late initiation of treatment with Risperdal Consta in subjects with schizophrenia after an acute episode • Researcher: Investigating the role of Quetiapine in Prevention of Manic Relapse • PhD Student ((“Antipsychotics and Schizophrenia: A model for obesity?”, Supervision by Professor Lyn Pilowsky and Professor Janet Treasure) • Nurse facilitator, Outpatients Weight Management Group July 2000- October 2004: • Clinical Research Nurse (“H” Grade); Section of Neurochemical Imaging and Psychiatry, Institute of Psychiatry, DeCrespigny Park, London SE5 8AF • Nurse Specialist attached to Maudsley Medication Review Clinic • Research and Management of Atyical Dietary Advice Service, South London and Maudsley Trust, investigating mechanisms of weight gain and control in people treated with antipsychotic medication, • Clinical Supervisor for Physical Health and Weight Management Programme, Brixton CMHT • PhD student (“Antipsychotics and Schizophrenia: A model for obesity?”, Supervision by Professor Lyn Pilowsky and Professor Janet Treasure) (M Phil upgrade approved) • Nursing Manager, FIRST Team (Southwark First Episode Psychosis Team) (July 2000January 2003) • Developing and implementing a Family/Carers education and support programme for first episode patients, group facilitator and co-facilitator for carers’ groups • Researcher, investigating mechanisms of endocrinological drug action in people treated with antipsychotic medication February 1995 – July 2000: Clinical Nurse Practitioner (“G” Grade); Maudsley Hospital, Denmark Hill, London (South London and Maudsley NHS Trust) • Nursing Manager, Maudsley Hospital Clozapine Clinic • Nurse Specialist attached to Maudsley Medication Review Clinic (formerly Atypical Antipsychotic Clinic) • Nurse Specialist for Electrocardiography, Maudsley Hospital • Nurse Practitioner for Outpatients Department, Maudsley Hospital August 1993 – February 1995: (Maternity Leave December 1993 – September 1994) Staff Nurse / Charge Nurse / Community Psychiatric Nurse; Grosvenor Nursing Agency, Denmark Hill, London • Staff/Charge Nurse, Tottenham Mews Day Hospital
February 1993 – August 1993: Office Manager, Grosvenor Nursing Agency, Hornsey Road, London N7 • Allocation of nurses to various posts • Office Management • Staff Management January 1992 – February 1993: Staff Nurse / Charge Nurse / CPN, Grosvenor Nursing Agency, Denmark Hill, London • CPN West Lambeth Community Mental Health Team (elderly) December 1990 – December 1991: Clinical Nurse Specialist, Department of Psychiatry, The Prince Henry Hospital, Malabar, NSW Australia • Nurse Specialist attached to Mood Disorder Unit • Community Liaison Nurse for Inpatient Psychiatry Unit • Programme Coordinator March 1990 – December 1990: Charge Nurse / Acting Deputy Director of Nursing, Wesley Private Hospital, Ashfield, NSW, Australia • Staff Development and Training Nurse • Infection Control Nurse • Quality and Audit Manager July 1987 – March 1990: Clinical Nurse Specialist / Programme Coordinator, Acute Admissions, The Rozelle Hospital, Leichhardt, NSW Australia • Clinical Nurse Specialist attached to Acute Admissions Unit • Programme Coordinator (Acute Admissions): included development and implementation of comprehensive patient education, support and activity programme • Family/Carer Education Committee Member. Co-author of a manual for carers of people with mental illness, group facilitator for carers’ groups (1988-90) • Hospital Union representative (NSW Nurses’ Association) July 1985 – July 1987: Medical Representative, Bayer Pharmaceuticals, Botany, NSW, Australia November 1982 – July 1985: Trainee Psychiatric Nurse / Staff Nurse / Charge Nurse, The Rozelle Hospital, Leichhardt, NSW, Australia May 1981 – November 1982: Staff Nurse / Charge Nurse, Neurosurgery & Neurosurgical Intensive Care Unit, The Royal Prince Alfred Hospital, Camperdown, NSW, Australia May 1978 – May 1981:
Trainee General Nurse, The Royal Prince Alfred Hospital, Camperdown, NSW, Australia
Education and Training:
February 2006: Good Clinical Practice (GCP) training March 2003: Qualitative Research Methods (MSc module) July 2002: SPSS training (Institute of Psychiatry) March 2001: PECC Training University Hospital, Kortenberg, Belgium 2000: Diploma of Nutrition and Diet Theory ITEC, London 1999: Advanced ECG Interpretation and Monitoring King’s College, London 1998: Medication Management Kings College, London 1996: Phlebotomy Training Maudsley Hospital, London 1985: Human Skills Development (Counselling) Sydney University, Camperdown, NSW November 1982 – July 1985: Trainee Psychiatric Nurse / Staff Nurse / Charge Nurse, The Rozelle Hospital, Leichhardt, NSW, Australia 1978 – 1981: General Nurse Training Royal Prince Alfred Hospital, Camperdown, NSW, Australia 1971 – 1976 Abbotsleigh School, Wahroonga, NSW, Australia Higher School Certificate 1976 (“A” Level equivalent) English, Ancient History, German : Grade A Mathematics, French: Grade B Grants held Production of a paper on aripiprazole and antipsychotic-weight gain. Bristol-Myers Squibb Pharmaceuticals Limited, Aitchison KJ (Principal Investigator), Ohlsen R, October 2007: £24,000 Production of a book on Medication Management with co-authors. Martin Dunitz Publishers, Ohlsen RI, Pilowsky LS, Smith S, Taylor DM, November 2002 (£2,000 each)
Setting up and management of a first episode psychosis team in Southwark. AstraZeneca Plc. Pilowsky LS (Principal Investigator), Ohlsen RI. January 2001: £260,000 Setting up and running of a weight management clinic for patients on antipsychotic medication. Novartis Pharmaceuticals, Pilowsky LS (Principal Investigator), Ohlsen R, July 2000: £25,000 Setting up and running of a weight management clinic for patients on antipsychotic medication. AstraZeneca Plc, Pilowsky LS (Principal Investigator), Ohlsen R, July 2000: £20,000 Setting up and running of a weight management clinic for patients on antipsychotic medication. Janssen-Cilag Ltd, Pilowsky LS (Principal Investigator), Ohlsen R, July 2000: £16,000 Research projects: 1997-1998: Clozaril Patient Audit Programme, assisting in developing an adverse effects measure 1999: Assessing the use of quetiapine in a population of treatment resistant patients in a naturalistic setting 2000 -2003: Open Study using dietary advice exercise and a psychosocial intervention (based on Motivational Interviewing and Compliance Therapy) to effect and maintain weight loss in overweight people on antipsychotic medication January 2001 – January 2003: F1RST Study (assessing the effect of quetiapine in patients suffering their first episode of psychosis) 2002-2005: Assessing genetic variables predicating weight gain and reponse to intervention in antipsychotic treated people 2004-2006: Assessing the role of quetiapine in prevention of manic relapse 2005-2006: Assessing and iImproving womens’ knowledge about contraception audit 2007: Analysis of data from the interrater reliability study of the ANNSERS and preparation of material for publication. 2007-2008: Assisting with development of training package for the ANNSERS including generation of videotapes. 2008: Assisting with generation of training videos for other clinical rating scales 2009: Association of BDNF Val66Met polymorphism and antipsychotic induced weight gain 2010: Association with BDNF Val66Met polymorphism and antipsychotic induced weight gain in a first episode population 2011: The influence of self-stigma on the dietary habits and physical activity of patients with psychosis A comparison Quality of Life and Self Esteem in patients with affective, non-affective and mixed psychotic disorders
Peer-Reviewed Publications: Brebion G, Ohlsen RI, Pilowsky LS, David AS. Serail and semantic coding of lists of words in schizophrenia patients with visual hallucinations. Psychiatry Res 2010 Sep 2 (Epub ahead of print)
Tsapakis EM, Curran S, Ohlsen RI, Vyas N, Aitchison KJ. Pharmacogenetics in Psychiatry. In: Maitland-van der Zee, A-H and Daly A (eds), "Pharmacogenetics and individualized therapy," John Wiley, in press. Ohlsen RI, Mir A, Shivakumar K, McAllister VDM, O’Keane V, Aitchison KJ (under review). Changes in metabolic parameters in a prospective aripiprazole add-on or switching study. Brebion G, Bressan RA, Ohlsen RI, Pilowsky LS, David AS (2010). Production of atypical category exemplars in patients with schizophrenia. J Int Neuropsychol Soc 16(5):822-8
Ohlsen RI, Aitchison KJ. The pharmacological management of bipolar affective disorder. MIMS Advances in Bipolar Disorders, Issue 1, March 2009 Brebion G, David AS, Bressan RA, Ohlsen RI, Pilowsky LS (2008). Hallucinations and two types of free-recall intrusion in schizophrenia. Psychol Med, 11:1-10 Ohlsen RI, Taylor D, Tandon K, Aitchison KJ (2008). Returning to the issue of the costeffectiveness of antipsychotics in the treatment of schizophrenia. Clinical Neuropsychiatry, 5(4):184-194 Ohlsen RI, Williamson RJ, Yusufi B, Mullan J, Irving D, Mukherjee S, Page E, Aitchison KJ, Barnes TR (2008). Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. J Psychopharmacol, 22(3):323-9 Brebion G, Ohlsen RI, Pilowsky LS, David AS (2008). Visual hallucinations in schizophrenia: confusion between imagination and perception. Neuropsychology , 22(3):383-9 Brebion G, David AS, Jones HM, Ohlsen R, Pilowsky LS. Temporal context discrimination in patients with schizophrenia: Associations with auditory hallucinations and negative symptoms. Neuropsychologia, 2007;45(4):817-23 Streeruwitz A, Barnes TRE, Fehler J, Ohlsen RI, Curtis VA (2007). Pharmacological management of acute mania – does current prescribing practice reflect treatment guidelines? J Psychopharmacol, 21(2):206-9 Ohlsen RI, Pilowsky LS (2007). Gender and Psychopharmacology (pp 238-252) In “The Female Body in Mind: The interface between the female body and mental health” ed. Mervat Nasser, Karen Baistow and Janet Treasure. Routledge, London, 2007 Ohlsen RI, Peacock G, Smith S (2005). Developing a Service to Monitor and Improve Physical Health in People with Serious Mental Illness. J Psychiatr Ment Health Nurs, 12(5):614-9 Ohlsen RI, Pilowsky LS (2005). Place of partial agonism in psychiatry: recent developments. J Psychopharmacol, 19(4):408-413
Jones HM, Brammer MJ, OToole M, Taylor T, Ohlsen RI, Brown RG, Purvis R, Williams S, Pilowsky LS (2004) Cortical effects of quetiapine in first episode schizophrenia; preliminary functional magnetic resonance imaging study. Biol Psychiatry 15;56(12):938-42 Ohlsen RI, O’Toole MS, Taylor TM, Purvis RG, Walters JT, Jones HM, Pilowsky LS (2004). Clinical effectiveness in first episode patients. Eur Neuropsychopharmacol, 14 Suppl 4 S445-41 Ohlsen RI, Pilowsky LS (2004). Models of Service Delivery in Early Intervention Teams: UK Variations (pp 145-155). In Best Care in Early Psychosis Intervention. ed. Ehmann T, McEwan B and Honer WG. Taylor and Francis Publishing Group, Oxon, 2004 Ohlsen RI, Treasure J, Pilowsky LS (2004). Re: Werneke U, Taylor, D, Sanders T et al. Behavioural management of antipsychotic induced weight gain: a review. Acta Psychiatr Scand, 109(2):156 O’Toole MS, Ohlsen RI, Taylor TM, Purvis RG, Walters J, Pilowsky LS (2004). Treating first episode psychosis - the service users’ perspective: a focus group evaluation. J Psychiatr Ment Health Nurs,11(3):319-26 Ohlsen RI, Treasure J, Pilowsky LS (2004). A dedicated nurse-led service for antipsychotic induced weight gain: an evaluation. Psychiatr Bull, 28:164-166 Howes O, Ohlsen R, Pilowsky LS (2003). The effect of clozapine on mortality. Br J Psychiatry 183:460 Taylor TM, O’Toole MS, Ohlsen RI, Walters J, Pilowsky LS (2003). Safety of quetiapine during pregnancy. Am J Psychiatry, 160: 588-589 Ruth Ohlsen, Shubulade Smith, David Taylor, Lyn Pilowsky (2002) The Maudsley Antipsychotic Medication Review Service Guidelines. Martin Dunitz, London, 2002 Stone, J, Ohlsen RI, Taylor DM, Pilowsky LS (2002). A naturalistic study of the Antipsychotic Medication Review Service at the Maudsley Hospital. Psychiatr Bull, 26:291-294 Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinov S, Kerwin RW, Pilowsky LS (2000). Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I] epidipride single photon emission tomography (SPET) study. Psychopharmacol (Berl), 150(2):132-40 ABSTRACTS/CONFERENCE PRESENTATIONS Cattaneo, A; Mondelli, V; Dazzan, P, Ohlsen RI et al.(2010). Inflammatory and neurotrophic factors unbalance in leukocytes of first episode psychosis patients. J Psychopharmacology 24; A12 Ohlsen, RI, Luzi, S, et al. (2010). BDNF val66met and antipsychotic-induced weight gain: a preliminary analysis. J Psychopharmacology 24 A44
Author(s. Ohlsen RI, Mir A, Shivakumar K, McAllister VDM, Aitchison KJ (2009). Changes in metabolic parameters in a prospective aripiprazole add-on or switching study. J Psychopharmacol 23(6, Abstract Supplement): A65
Streeruwitz, A, Barnes TRE, Fehler, J, Ohlsen, R, Curtis VA (2006) How is acute mania treated? A cross-sectional survey in 4 London hospitals Bipolar Disord. 7: 104-104 Suppl. Ohlsen, R, Peacock, G, Smith, S, et al. Assessing physical health in an urban population of people with serious mental illness. Schizophrenia Bull 31 (2): 567-567 Apr 2005 Purvis, R, Ohlsen, R, Pilowsky, L, et al. A temporal sequence to recovery in first episode psychosis. Schizophrenia Bull 31 (2):340-340 Apr 2005 Ohlsen RI, Smith S, Peacock G. The Well-Being Support Programme: Basic Nutritional Advice in Patients with Serious Mental Illness. J Psychopharmacol 18(3): A59-A59 Suppl. S SEP 2004 Smith S, Peacock G, Ohlsen R. Physical Health in Patients with Severe Mental Illness. J Psychopharmacol 18(3): A58-A58 Suppl. S SEP 2004 Ohlsen RI, Walters JT, O’Toole MS et al. Clinical Response after switching from twice to once daily quetiapine in first episode schizophrenic patients : support for the “transient D2 occupancy” model. Schizophr Res 67 Purvis, RG, Jones, HM, Ohlsen, RI, et al. Neurocognitive change in first-episode psychosis. Schizophr Res 53 (3): 124-124 Sp. Iss. SI Suppl. S Jan 15 2002 Ohlsen, RI, Jones, HM, Ohlsen, JC, et al. Antipsychotic induced weight gain: Gender differences in response to intervention. Schizophr Res 53 (3): 159-159 Sp. Iss. SI Suppl. S Jan 15 2002 Taylor, T, O'Toole, MS, Ohlsen, RI, et al. Quality of life, well-being, side effects and compliance with quetiapine, in the treatment of first-episode psychosis Schizophr Res 53 (3): 161-161 Sp. Iss. SI Suppl. S Jan 15 2002 O'Toole, MS, Taylor, T, Ohlsen, RI, et al. Quetiapine treatment of first-episode psychosis - The Southwark first onset psychosis service (first) - A preliminary audit of psychotic symptoms. Schizophr Res 53 (3): 181-182 Sp. Iss. SI Suppl. S Jan 15 2002 Purvis RG, Ohlsen R, O’Toole MS et al. Real-world functional outcome in schizophrenia. A goaldirected behaviour model. Schizophr Res 67 (1): 200-200 Suppl S Feb 15 2004 Ohlsen R, Pilowsky L. Failure of a psychosocial intervention to effect significant weight loss in people with antipsychotic induced obesity. Obes Res 11: A152-A152 Suppl S Sep 2003
Jones HM, Brammer MJ, Ohlsen R et al. Effects of quetiapine in first episode schizophrenia. Comparison with drug-naïve patients and healthy controls. Biol Psychiat 53 (8):233 Suppl. S Apr 15 2003 Purvis RG, Ohlsen RI, O’Toole MS et al. A goal directed behaviour model of neurocognitive and behavioural functioning in first episode psychosis- A preliminary report of the FIRST study. Schizophr Res 60(1):153-153 Suppl S Mar 15 2003 Jones HM, Brammer MJ, Ohlsen R et al. Effects of quetiapine in first episode schizophrenia. Comparison with drug naïve patients and healthy controls. Schizophr res 60 (1)224-225 Suppl S Mar 15 2003 O’Toole M, Taylor T, Walters J et al. The Southwark First Onset Psychosis Service (FIRST)- A longitudinal prospective follow-up study of quetiapine treatment in first episode schizophrenia. Schizophr Res 60 (1) :327-327 Suppl S Mar 15 2003 Taylor T, O’Toole M, Walters J, Ohlsen RI et al. A prospective follow-up of quality of life, wellbeing, side effects and compliance in the treatment of first episode psychosis. Schizophr Res 60 (1):329-329 Suppl S Mar 15 2003 Walters JT, Hanlon C, Taylor T, O’Toole MS, Ohlsen RI et al. Is FIRST best ? A preliminary study of the effectiveness of the Southwark First Episode Psychosis Team (FIRST) versus standard care. Schizophr Res 60 (1) 331-331 Suppl S Mar 15 2003 Bell R, Ohlsen RI, O’Toole MS et al. Developing a job coaching programme for first onset psychosis patients in the Southwark First Episode Psychosis Service (FIRST). Schizophr Res 60 (1): 332-332 Suppl S Mar 15 2003 Winter KM, Ohlsen RI, Bell R et al. Developing a healthy lifestyle/fitness programme for people with serious mental illness. Schizophr Res 60 (1): Suppl S Mar 15 2003 Ohlsen RI, Jones HM, Ohlsen JC et al. Gender differences in response to a weight management intervention are not upheld up to twelve months. Schizophr Res 60 (1): 364-364 Suppl S Mar 15 2003 Ohlsen RI, Jones HM, Ohlsen JC. Antipsychotic induced weight gain:Gender differences in response to psychosocial intervention. J Psychopharmacol 16 (3):A45 Suppl S Sep 2002 Ohlsen RI, O’Toole MS, Taylor T et al. Developing a new first episode psychosis service for an inner city population. Schizophr Res 60 (1): 364-364 Suppl S Mar 15 2003 Purvis RG, Jones HM, Ohlsen RI et al. Qualitative and quantitative measures of activity in first episode psychosis: A framework for assessment. Schizophr Res 53 (3): 53-53 Suppl S Jan 15 2002 Purvis RG, Jones HM, Ohlsen RI. Neurocognitive change in first episode psychosis. Schizophr Res 53 (3): 124-124 Sp Iss SI Suppl S Jan 15 2002
Ohlsen RI, Jones HM, Ohlsen JC et al. Antipsychotic induced weight gain: Gender differences in response to intervention. Schizophr Res 53 (3): 124-124 Sp Iss SI Suppl S Jan 15 2002 Taylor T, O’Toole MS, Ohlsen RI et al. Quality of life, well-being, side effects and compliance with quetiapine in the treatment of first episode psychosis. Schizophr Res 53 (3): 161-161 Sp Iss SI Suppl S Jan 15 2002 O’Toole MS, Taylor T, Ohlsen RI et al. Quetiapine treatment of first episode psychosis-The Southwark first onset psychosis service (FIRST)- A preliminary audit of psychotic symptoms. Schizophr Res 53 (3): 181-182 Sp Iss SI Suppl S Jan 15 2002 Jones HM, Williams SC, Brammer MJ et al. An fMRI study of the effect of quetiapine treatment on cortical activation in schizophrenia. Schizophr Res 53 (3): 188-189 Sp Iss SI Suppl S Jan 15 2002 Ohlsen RI, Jones HM, Ohlsen JC et al. Longitudinal follow up on a weight loss intervention for overweight people on antipsychotic medication. Schizophr Res 53 (3): 253-254 Sp Iss SI Suppl S Jan 15 2002 Ohlsen RI, Jones HM, Pilowsky LS. A preliminary report on a nurse-led pilot study aimed at facilitating weight loss in schizophrenic people on antipsychotic medications. Schizophr Res 53 (3): 288-288 Sp Iss SI Suppl S Jan 15 2002 Smith S, Jones HM, Bigliani V et al. The atypical antipsychotic clinic-Evaluating a new service for treating schizophrenia. Schizophr Res 41 (1): B98 Sp. Iss. SI Jan 3 2000 Contribution towards public understanding of science Ohlsen Ruth, Barton, Cheryl (2007) Drug Delivery Technology: Revolutionising CNS Therapies. Pharmavision: commercial report for industry. Involvement with a carers group (Rethink for their Magazine “Your Voice”) Ohlsen Ruth (2006) Diet and Mental Illness: can it make a difference? In Your Voice Ohlsen, Ruth (2006) Smoking and mental illness: why? In Your Voice CONSULTANCY WORK Consultancy work for AstraZeneca, Bristol-Myers Squibb Pharmaceuticals Limited, Eli Lilly, Janssen-Cilag, Novartis, Sanofi-Aventis. INVITED TALKS December 2000: Australian Congress of Mental Health Nurses March 2009: University of Sao Paulo, Brazil, Multidisciplinary Conference for Mental Health November 2009: 2nd Conference on Neurobiology, Thessaloniki, Greece In addition I have been an invited lecturer to academic meetings within the IOP and SLAM, and at pharmaceutical company sponsored events and conferences
TEACHING AND MANAGEMENT EXPERIENCE Management: Nurse Supervisor (2004-2005) Brixton Well Being Support Clinic Manager: Southwark First Episode Psychosis Team: January 2001-January 2003 Office Manager: Grosvenor Nursing Agency, February 1992 -August 1992 Teaching, Lecturing: 2010: Supervision of 2 MSc students (King’s College) Lecturer for Maudsley Forum (Psychopharmacology) 2009 and 2010 Regular lecturing and Rating Scale Training Courses and Concordance Training for clinicians in NHS Trusts across the UK and within SLAM, including psychopharmacology, weight management, side effect management, first episode psychosis management, management of patients on clozapine I have trained clincians throughout SLAM in performing ECGs Production of Video Training Aids for Rating Scales for Researchers and NHS clinicians Occasional lecturing within Kings College (MSc course (Gender and Psychopharmacology), Student Nursing Course (Psychopharmacology, Gender and Psychopharmacology), Consultant CPD Course, Academic Meetings, Psychosis Interest Group, and Education within South London and Maudsley Trust) I have lectured for the King’s College Medication Management Course, and lectured for the “Train the Trainers” Medication Management Course I initiated and Chaired the IOP Obesity Interest Group (2006-7), have been a member of the London Early Intervention Network, and a committee member for the Southwark First Episode Steering Group and the Clozapine Nurse Forum I have presented work and lectured at many educational academic meetings for NHS Trusts and Pharmaceutical Companies, and been an invited speaker at many national and international conferences. I continue to do this on an ongoing basis. I have also participated regularly as an invited panel member on Pharmaceutical Advisory Boards. Referees Can be provided upon request.